Healthcare entity
All 1 tracked stories fall under one category: acquisition. Of the tracked stories, 1 of 1 also mention Aurobindo Pharma Ltd., the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline.
Last mentioned: Jul 27, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: acquisition. Of the tracked stories, 1 of 1 also mention Aurobindo Pharma Ltd., the most common co-covered peer. Source depth averages 2 original sources per story, versus 2.2 across the same-window beat baseline. The average consequence score is 6, matching the 6 beat baseline for this window. Aurobindo Pharma USA, Inc. appears in 1 tracked Healthcare story from July 27, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Aurobindo Pharma USA, Inc.. Shared-story counts are live from our verified record — not editorial picks.
FTC approval paves the way for Aurobindo Pharma to acquire Lannett Company, adding a 4 billion dose manufacturing facility and complex non-opioid generics portfolio to its network, directly supporting US efforts to boost domestic drug production and address the opioid crisis.
Aurobindo Pharma USA, Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
